H.C. Wainwright analyst Douglas Tsao revised the price target for Sage Therapeutics (NASDAQ:SAGE) to $12.00 from the previous $14.00 while maintaining a Neutral rating on the company's shares. Tsao's ...
Throughout the last three months, 7 analysts have evaluated Sage Therapeutics (NASDAQ:SAGE), offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of ...
Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Sage Therapeutics in a ...
Sage Therapeutics, Inc. SAGE reported a loss of $1.56 per share for the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.45. The company had reported a loss of 55 ...
Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.56 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $0.55 per share a year ago.
Canaccord Genuity has adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) by reducing the stock's price target to $8.00 from the previous $9.00, while maintaining a Hold rating on the shares. The ...
NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
Analysts at Leerink Partnrs issued their Q3 2025 earnings estimates for Sage Therapeutics in a research report issued to clients and investors on Tuesday, February 11th. Leerink Partnrs analyst M.
Sage Advisors LLC lessened its holdings in Broadcom Inc. (NASDAQ:AVGO – Free Report) by 14.9% during the fourth quarter, ...
We recently compiled a list of the 10 Best Low Priced Stocks to Invest in Now. In this article, we are going to take a look ...
Sage Capital Advisors llc lifted its position in shares of Microsoft Co. (NASDAQ:MSFT – Free Report) by 0.2% during the ...